CDK9 and cancer: In addition, Atuveciclib, a selective PTEFb/CDK9 inhibitor, and CT7001, a selective CDK7 inhibitor, are emerging as potential cancer treatment options, as they have entered clinical trials (Lucking et al., 2017; Sava et al., 2020).